Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
1 finding from 1 review
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
1 finding from 1 review
Progression‐free survival · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to lower progression‐free survival (absolute effect size estimates based on… compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with placebo (targeted agent versus placebo) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
1 finding from 1 review
Health‐related quality of life · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
1 finding from 1 review
Progression‐free survival · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower progression‐free survival (absolute effect size estimates based on… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis
It is very uncertain whether ciprofloxacin changes clinical efficacy ‐ cure or improvement at end of treatment compared with comparator fluoroquinolone (very low certainty).
2 findings from 1 review
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Ciprofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
1 finding from 1 review
Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis
It is very uncertain whether levofloxacin changes microbiological efficacy ‐ pathogen eradication compared with comparator fluoroquinolone (very low certainty).
1 finding from 1 review
Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis
2 findings from 1 review
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
1 finding from 1 review
Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis
Lomefloxacin showed no clear difference in microbiological efficacy ‐ pathogen eradication at compared with comparator fluoroquinolone (low certainty).
1 finding from 1 review
Clinical efficacy ‐ cure or improvement at · patients with chronic bacterial prostatitis
2 findings from 1 review
Adverse effects of treatment ‐ any adverse effects · patients with chronic bacterial prostatitis
Lomefloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).
1 finding from 1 review
Microbiological efficacy ‐ pathogen eradication · patients with chronic bacterial prostatitis
It is very uncertain whether ciprofloxacin changes microbiological efficacy ‐ pathogen eradication at end of treatment compared with comparator fluoroquinolone (very low certainty).
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review